Literature DB >> 9571042

Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest.

J McLaurin1, T Franklin, A Chakrabartty, P E Fraser.   

Abstract

A key pathological feature of Alzheimer's disease is the formation and accumulation of amyloid fibres. The major component is the 39 to 42 residue amyloid-beta peptide (Abeta) which is an internal proteolytic fragment of the integral membrane amyloid precursor protein. Aggregation of Abeta into insoluble amyloid fibres is a nucleation-dependent event that may be modulated by the presence of amyloid-associated molecules. Fibril formation is also associated with neurotoxicity which may be the result of specific Abeta interactions with membrane proteins and/or lipids. Using circular dichroism spectroscopy, tyrosine fluorescence spectroscopy and electron microscopy, we have examined the binding of Abeta peptides 1-40 (Abeta40) and 1-42 (Abeta42) to the glycolipid, phosphatidylinositol (PI), and different inositol headgroups. At pH 6.0 and in the presence of PI vesicles, both Abeta40 and Abeta42 adopted an amyloidogenic beta-structure. In contrast, at neutral pH only Abeta42 folded into a beta-structure in the presence of PI vesicles. To determine whether the induction of beta-structure stemmed from interactions with the headgroup of PI, the effects of inositol derivatives on Abeta were also examined. At pH 7.0, myo-inositol was sufficient to induce beta-structure in Abeta42 but had no effect on the conformation of Abeta40. Myo-inositol may promote beta-structure as a result of its ability to be both a hydrogen-bond donor and acceptor. Mono-, di- and triphosphorylated forms of inositol had reduced ability to induce beta-structure in both peptides. The results from this study indicate that interaction of Abeta40 and Abeta42 with PI acts as a seed for fibril formation while myo-inositol stabilizes a soluble Abeta42 micelle. Copyright 1998 Academic Press Limited.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9571042     DOI: 10.1006/jmbi.1998.1677

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  28 in total

1.  Ultrastructural characterization of peptide-induced membrane fusion and peptide self-assembly in the lipid bilayer.

Authors:  A S Ulrich; W Tichelaar; G Förster; O Zschörnig; S Weinkauf; H W Meyer
Journal:  Biophys J       Date:  1999-08       Impact factor: 4.033

2.  Designing conditions for in vitro formation of amyloid protofilaments and fibrils.

Authors:  F Chiti; P Webster; N Taddei; A Clark; M Stefani; G Ramponi; C M Dobson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 3.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

Review 4.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

Review 5.  The "Other" Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry).

Authors:  Mark P Thomas; Stephen J Mills; Barry V L Potter
Journal:  Angew Chem Int Ed Engl       Date:  2015-12-22       Impact factor: 15.336

6.  Aβ(1-42) assembly in the presence of scyllo-inositol derivatives: identification of an oxime linkage as important for the development of assembly inhibitors.

Authors:  J E Shaw; J Chio; S Dasgupta; A Y Lai; G C H Mo; F Pang; L A M Thomason; A J Yang; C M Yip; M Nitz; J McLaurin
Journal:  ACS Chem Neurosci       Date:  2011-12-23       Impact factor: 4.418

7.  Lipid-induced conformational transition of amyloid beta peptide fragments.

Authors:  Nagarajan Sureshbabu; R Kirubagaran; H Thangarajah; E J Padma Malar; R Jayakumar
Journal:  J Mol Neurosci       Date:  2010-05-18       Impact factor: 3.444

Review 8.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Comparative studies on peptides representing the so-called tachykinin-like region of the Alzheimer Abeta peptide [Abeta(25-35)].

Authors:  O M El-Agnaf; G B Irvine; G Fitzpatrick; W K Glass; D J Guthrie
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

10.  Identification of myo-inositol-3-phosphate synthase isoforms: characterization, expression, and putative role of a 16-kDa gamma(c) isoform.

Authors:  Ratnam S Seelan; Jaganathan Lakshmanan; Manuel F Casanova; Ranga N Parthasarathy
Journal:  J Biol Chem       Date:  2009-02-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.